-
Recombinant NSD2-SET (E1099K) protein
Recombinant NSD2-SET (E1099K) protein
- 中文名称：
- Recombinant NSD2-SET (E1099K) protein
- 英文名称：
- Recombinant NSD2-SET (E1099K) protein
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59758
- 规格：
- 0.05 mg|1 mg|2x1 mg|3x1 mg|4x1 mg
- 保存建议：
- Recombinant proteins in solution are temperature sensitive and must be stored at -80 degree C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Shipping Temp: Dry Ice
- 货期：
- 6-8周
- 纯度：
- The purity of NSD2-SET (E1099K) protein is >85% pure by SDS-PAGE.
- 产品形式：
- Recombinant NSD2-SET (E1099K) protein is suppled in 50mM Tris pH8.0, 300mM NaCl, 5% glycerol.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Short Description: Recombinant human NSD2-SET (E1099K) includes amino acids 942-1240 (accession number NP_579877.1) was expressed in E Coli with a point mutation (Glu1099Lys) and an N-terminal GST-Tag. The molecular weight of the protein is 60 kDa. NSD2-SET (E1099K) protein is >85% pure by SDS-PAGE. It is suitable for use in the study of enzyme kinetics, inhibitor screening, and selectivity profiling.
Background: NSD2 (nuclear receptor binding SET domain protein 1; also known as WHSC1; MMSET; TRX5) is a SET domain-containing histone methyltransferase specific for lysine 36 of histone H3. The NSD2 gene is deleted in Wolf-Hirschhorn syndrome, a disorder characterized by developmental defects and mental retardation. In 15% of patients with Multiple Myeloma (MM), a chromosomal translocation leads to NSD2 gene being aberrantly placed under the control of the IgH intronic u enhancer and expressed at very high levels. This event is apparently a key component in cellular transformation leading to MM. Reduction in NSD2 expression in a myeloma cell line suppressed its growth, suggesting a role for NSD2 in maintaining the transformed state. NSD2 p.Glu1099Lys (p.E1099K) variant was identified in nontranslocated acute lymphoblastic leukemia (ALL) cell lines.
